Nasdaq · CIK 0001737287
ALLO Allogene Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing Jun 23, 2025. Close $1.46 on Oct 9, 2026, +39% from the 52-week low and -52% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
15
with a Form 4 at this company
Price and insider trades, last year
ALLOOct 9, 2026 · close 1.46
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Allogene Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 12Weak | Deborah M. Messemer director sell | $52k 36,885 shares | -26% | +54% from low-55% from high | |
| 15Weak | Annie Yoshiyama SVP, Finance sell | $14k 9,601 shares | -7% | +4% from low-56% from high | |
| 23Weak | Benjamin Machinas Beneski SVP, Chief Technical Officer sell | $11k 5,488 shares | -2% | +39% from low-40% from high | |
| 42Moderate | David D Chang President and CEO sell | $91k 46,668 shares | -1% | +39% from low-40% from high | |
| 0Weak | Deborah M. Messemer director sell | $32k 13,313 shares | -8% | +103% from low-12% from high | |
| 35Weak | Zachary Roberts EVP of R&D sell | $32k 18,832 shares | -3% | 0% from low-48% from high | |
| 48Moderate | David D Chang President and CEO sell | $77k 46,003 shares | -1% | 0% from low-48% from high | |
| 35Weak | Timothy L. Moore Chief Technical Officer sell | $25k 14,746 shares | -6% | 0% from low-48% from high | |
| 37Weak | Geoffrey M. Parker CHIEF FINANCIAL OFFICER sell | $7,545 4,361 shares | -0% | 0% from low-48% from high | |
| 30Weak | Earl Martin Douglas SVP, General Counsel sell | $11k 6,404 shares | -1% | 0% from low-48% from high | |
| 37Weak | Zachary Roberts EVP of R&D sell | $48k 27,199 shares | -5% | +1% from low-43% from high | |
| 3Weak | Deborah M. Messemer director sell | $20k 9,136 shares | -5% | - | |
| 23Weak | Franz B Humer director sell | $20k 9,221 shares | -3% | - |
Transactions
The last 35 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 18, 2025 | Owen N. Witte director | AGrant or award Restricted Stock Unitderivative | +95,400 | $0.00 | $0 | 95,400 | Jun 23, 2025 |
| Jun 18, 2025 | Stephen Mayo director | AGrant or award Restricted Stock Unitderivative | +95,400 | $0.00 | $0 | 95,400 | Jun 23, 2025 |
| Jun 18, 2025 | Elizabeth A. Barrett director | AGrant or award Restricted Stock Unitderivative | +95,400 | $0.00 | $0 | 95,400 | Jun 23, 2025 |
| Jun 18, 2025 | Franz B Humer director | AGrant or award Restricted Stock Unitderivative | +95,400 | $0.00 | $0 | 95,400 | Jun 23, 2025 |
| Jun 18, 2025 | Deborah M. Messemer director | AGrant or award Restricted Stock Unitderivative | +95,400 | $0.00 | $0 | 95,400 | Jun 23, 2025 |
| Jun 18, 2025 | Vicki L Sato director | AGrant or award Stock Option (Right to buy)derivative | +144,400 | $0.00 | $0 | 144,400 | Jun 23, 2025 |
| Jun 18, 2025 | Joshua A Kazam director | AGrant or award Restricted Stock Unitderivative | +94,500 | $0.00 | $0 | 94,500 | Jun 23, 2025 |
| Jun 10, 2025 | Deborah M. Messemer director | SOpen-market sale Common Stock10b5-1 | -36,885 | $1.42 | $52k | 107,431 | Jun 12, 2025 |
| Apr 21, 2025 | Annie Yoshiyama SVP, Finance | SOpen-market sale Common Stock | -9,601 | $1.41 | $14k | 130,663 | Apr 23, 2025 |
| Mar 14, 2025 | Benjamin Machinas Beneski SVP, Chief Technical Officer | SOpen-market sale Common Stock | -5,488 | $1.98 | $11k | 218,507 | Mar 18, 2025 |
| Mar 14, 2025 | David D Chang President and CEO | SOpen-market sale Common Stock | -46,668 | $1.96 | $91k | 5,276,569 | Mar 18, 2025 |
| Mar 1, 2025 | Benjamin Machinas Beneski SVP, Chief Technical Officer | AGrant or award Common Stock | +31,755 | $0.00 | $0 | 223,995 | Mar 5, 2025 |
| Mar 1, 2025 | Benjamin Machinas Beneski SVP, Chief Technical Officer | AGrant or award Stock Option (Right to buy)derivative | +112,339 | $0.00 | $0 | 112,339 | Mar 5, 2025 |
| Feb 18, 2025 | Deborah M. Messemer director | SOpen-market sale Common Stock10b5-1 | -13,313 | $2.43 | $32k | 144,316 | Feb 20, 2025 |
| Feb 3, 2025 | Geoffrey M. Parker CHIEF FINANCIAL OFFICER | SOpen-market sale Common Stock | -4,361 | $1.73 | $7,545 | 1,301,540 | Feb 5, 2025 |
| Feb 3, 2025 | Earl Martin Douglas SVP, General Counsel | SOpen-market sale Common Stock | -6,404 | $1.71 | $11k | 587,848 | Feb 5, 2025 |
| Feb 3, 2025 | David D Chang President and CEO | SOpen-market sale Common Stock | -46,003 | $1.68 | $77k | 5,317,237 | Feb 5, 2025 |
| Feb 3, 2025 | Zachary Roberts EVP of R&D | SOpen-market sale Common Stock | -18,832 | $1.70 | $32k | 643,135 | Feb 5, 2025 |
| Feb 3, 2025 | Timothy L. Moore Chief Technical Officer | SOpen-market sale Common Stock | -14,746 | $1.71 | $25k | 250,713 | Feb 5, 2025 |
| Jan 24, 2025 | Annie Yoshiyama SVP, Finance | AGrant or award Common Stock | +36,232 | $0.00 | $0 | 137,990 | Jan 28, 2025 |
| Jan 24, 2025 | Earl Martin Douglas SVP, General Counsel | AGrant or award Common Stock | +144,928 | $0.00 | $0 | 594,252 | Jan 28, 2025 |
| Jan 24, 2025 | Geoffrey M. Parker CHIEF FINANCIAL OFFICER | AGrant or award Common Stock | +173,913 | $0.00 | $0 | 1,305,901 | Jan 28, 2025 |
| Jan 24, 2025 | Zachary Roberts EVP of R&D | AGrant or award Common Stock | +173,913 | $0.00 | $0 | 661,967 | Jan 28, 2025 |
| Jan 24, 2025 | Arie Belldegrun director | AGrant or award Common Stock | +369,957 | $0.00 | $0 | 2,236,816 | Jan 28, 2025 |
| Jan 24, 2025 | David D Chang President and CEO | AGrant or award Common Stock | +552,174 | $0.00 | $0 | 5,363,240 | Jan 28, 2025 |
| Jan 24, 2025 | Zachary Roberts EVP of R&D | AGrant or award Stock Option (Right to buy)derivative | +614,844 | $0.00 | $0 | 614,844 | Jan 28, 2025 |
| Jan 24, 2025 | Annie Yoshiyama SVP, Finance | AGrant or award Stock Option (Right to buy)derivative | +128,093 | $0.00 | $0 | 128,093 | Jan 28, 2025 |
| Jan 24, 2025 | Geoffrey M. Parker CHIEF FINANCIAL OFFICER | AGrant or award Stock Option (Right to buy)derivative | +614,844 | $0.00 | $0 | 614,844 | Jan 28, 2025 |
| Jan 24, 2025 | Earl Martin Douglas SVP, General Counsel | AGrant or award Stock Option (Right to buy)derivative | +512,370 | $0.00 | $0 | 512,370 | Jan 28, 2025 |
| Jan 24, 2025 | David D Chang President and CEO | AGrant or award Stock Option (Right to buy)derivative | +1,952,130 | $0.00 | $0 | 1,952,130 | Jan 28, 2025 |
| Jan 24, 2025 | Arie Belldegrun director | AGrant or award Stock Option (Right to buy)derivative | +1,307,927 | $0.00 | $0 | 1,307,927 | Jan 28, 2025 |
| Jan 21, 2025 | Zachary Roberts EVP of R&D | SOpen-market sale Common Stock | -27,199 | $1.78 | $48k | 488,054 | Jan 23, 2025 |
| Dec 9, 2024 | Deborah M. Messemer director | SOpen-market sale Common Stock10b5-1 | -9,136 | $2.18 | $20k | 157,629 | Dec 10, 2024 |
| Dec 5, 2024 | Franz B Humer director | SOpen-market sale Common Stock | -9,221 | $2.16 | $20k | 307,507 | Dec 9, 2024 |
| Oct 21, 2024 | Geoffrey M. Parker CHIEF FINANCIAL OFFICER | FTax withholding Common Stock | -36,404 | $2.84 | $103k | 1,131,988 | Oct 23, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Elizabeth A. Barrettceo, officer, director
- Arie Belldegrundirector, owner
- Benjamin Machinas BeneskiSVP, Chief Technical Officer
- David D ChangPresident and CEO
- Earl Martin DouglasSVP, General Counsel
- Franz B Humerdirector
- Joshua A Kazamdirector
- Deborah M. Messemerdirector
- Timothy L. MooreChief Technical Officer
- Stephen Mayodirector
- Geoffrey M. ParkerCHIEF FINANCIAL OFFICER
- Zachary RobertsEVP of R&D
- Vicki L Satodirector
- Owen N. Wittedirector
- Annie YoshiyamaSVP, Finance
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.